

## Unaudited financial statements

### Statement of assets, liabilities, and partners' capital

June 30, 2024

Investments, at fair value (cost \$11,664,781)	\$ 17,781,991
Cash	410,115
Accounts receivable	577,844
Capital contributions receivable	314,962
Total assets	19,084,912
Liabilities and partners' capital	
Liabilities	
Due to related parties	887
	19,050
Тах	
<i>Tax</i> Accrued expenses	19,050
	<b>19,050</b> 236,686
Accrued expenses	

#### Partners' capital

Total partners' capital	18,718,682
Total liabilities and partners' capital	\$ 19,084,912

#### Schedule of investments

June 30, 2024

Investments, at fair value	Invt. date	Shares	Cost	Fair value	Unrealized gain (loss)	Co	st/share	Fair value/share
Ares Materials, Inc.								
Series A Preferred	06/27/2019	9,921,946	\$ 1,500,000	\$ 1,500,000	\$ —	\$	0.15	\$ 0.15
Biomakers, Inc.								
Series A-1 Preferred	01/26/2024	876,451	1,000,000	2,508,572	1,508,572		1.14	2.86
Compound Foods, Inc.		_	1,200,000	1,200,000	_		_	
SAFE	09/27/2020	_	200,000	200,000	_		_	_
SAFE	03/25/2021	_	1,000,000	1,000,000	_		_	_
Cubbo Holdings Limited								
Series Seed-1 Preferred	11/08/2021	856,245	900,000	1,982,514	1,082,514		1.05	2.32
DProtein Inc.		_	200,000	200,000	_		_	_
SAFE	07/23/2021	_	100,000	100,000	—		_	
SAFE	11/15/2022	—	20,000	20,000	—		—	_
SAFE	05/18/2023	_	80,000	80,000	_		_	_
Encellin, Inc.								
Series Seed-1 Preferred	06/28/2019	1,357,632	1,250,000	2,539,994	1,289,994		0.92	1.87
Equator Therapeutics, Inc.								
SAFE	12/14/2021	_	500,000	500,000	_		_	_
Fiado, Inc.		_	750,000	750,000	_		_	_
SAFE	08/03/2021	_	500,000	500,000	—		_	
SAFE	10/29/2021		250,000	250,000	_		_	_

### Schedule of investments (continued)

June 30, 2024

Investments, at fair value	Invt. date	Shares	Cost	Fair value	Unrealized gain (loss)	Cost/share	Fair value/share
Finless Foods Inc.		336,020	\$ 480,979	\$ 613,259	\$ 132,280	\$ —	\$ —
Series A-3 Preferred	09/11/2020	336,020	245,093	377,373	132,280	0.73	1.12
Convertible Promissory Note	04/22/2024	_	235,886	235,886	—	_	—
GEn1E Lifesciences Inc.		1,319,190	1,000,000	2,342,725	1,342,725	_	
Series Seed-3 Preferred	12/06/2022	520,724	500,000	924,760	424,760	0.96	1.78
Series Seed-4 Preferred	12/06/2022	798,466	500,000	1,417,965	917,965	0.63	1.78
Justo Inc.		953,670	647,640	600,812	(46,828)	_	
Series A Preferred	03/26/2021	86,454	73,820	54,466	(19,354)	0.85	0.63
Series A-9 Preferred	03/26/2021	780,762	500,000	491,880	(8,120)	0.64	0.63
Series A Preferred	08/26/2021	86,454	73,820	54,466	(19,354)	0.85	0.63
Musa Technology, LLC							
Series A-2 Preferred	09/30/2021	702,350	304,118	1,261,280	957,162	0.43	1.80
PRIXZ, INC.							
Series A-1 Preferred	04/15/2022	62,988	1,000,000	1,000,000	—	15.88	15.88
Retail Integrated Ltd DBA 'Mercé	è do Bairro'						
Series A Preference	09/02/2021	115,830	283,949	134,740	(149,209)	2.45	1.16
Torch Systems Inc.							
SAFE	11/10/2021	_	500,000	500,000	—	_	—
ZaxApp Holding Ltd.							
SAFE	12/22/2023	_	 148,095	148,095	_	_	
Total			\$ 11,664,781	\$ 17,781,991	\$ 6,117,210		

Schedule of investments (continued)

June 30, 2024

Asset type	Fair value as of June 30, 2024
Preferred stock	\$14,248,010
Convertible promissory note/SAFEs	3,533,981

### Statement of operations

Expenses	
Management fees	\$ 130,122
Other expenses	17,766
Fund administration fees	6,250
Total professional fees	6,250
Total expenses	154,138
Net investment loss	 (154,138)
Net realized and net change in unrealized gain (loss) on investments	
Net realized loss on investments	(887,011)
Net change in unrealized gain on investments	162,533
Net loss on investments	(724,478)
Net decrease in partners' capital from operations	\$ (878,616)

### Statement of changes in partners' capital

	General Partner	Limited Partners	Total
Partners' capital, beginning of period	\$ 723,860	\$ 18,873,438	\$ 19,597,298
Management fees	—	(130,122)	(130,122)
Net operating income (loss)	(782)	(23,234)	(24,016)
Net realized gain (loss)	(28,873)	(858,138)	(887,011)
Net unrealized gain (loss)	5,291	157,242	162,533
Partners' capital, end of period	\$ 699,496	\$ 18,019,186	\$ 18,718,682

#### Statement of cash flows

Net decrease in partners' capital from operations	\$ (878,616)
Adjustments to reconcile net decrease in partners' capital from operations to net cash used in operating activities:	
Net realized loss on investments	887,011
Net change in unrealized gain on investments	(162,533)
Purchase of investments	(235,886)
Proceeds from sale of investments	579,038
Changes in operating assets and liabilities:	
Increase in accounts receivable	(577,043)
Decrease in accrued expenses	(5,298)
Increase in accounts payable	235,886
Net cash used in operating activities	(157,441)
Cash flows from financing activities	
Capital contributions	31,367
Net cash provided by financing activities	 31,367
Net decrease in cash	(126,074)
Cash, beginning of period	536,188